{
    "clinical_study": {
        "@rank": "107433", 
        "arm_group": [
            {
                "arm_group_label": "Age 5-6.5", 
                "description": "Group 1 will consist of 16 children aged 5-6.5 years"
            }, 
            {
                "arm_group_label": "Aged 6.6- 8 years", 
                "description": "Group 2 will consist of 16 children aged 6.6- 8 years"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine ex vivo the amount of fluticasone\n      deposited onto a filter (delivered dose) interposed between the OptiChamber Diamond VHC\n      mouthpiece and the subject's mouth during coordinated and uncoordinated actuation/inhalation\n      maneuver."
        }, 
        "brief_title": "Drug Delivery Via Pressurized Metered-dose Inhaler and Valved Holding Chamber in Asthmatic Children: Determination of Delivered Dose Following Coordinated and Uncoordinated Use", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 Asthmatic children between the ages of 5 and 8 followed at Arkansas Children's\n             Hospital.\n\n               -  The subjects must be available to complete the study.\n\n               -  The subject's parent(s) and/or the subject's legal guardian must provide written\n                  informed consent to participate in the study.\n\n               -  The subject must provide assent when older than 7 years old.\n\n               -  The subjects should have used a pMDI VHC previously and be able to use a VHC\n                  with mouthpiece.\n\n               -  The subjects should have been prescribed fluticasone or another inhaled\n                  corticosteroid delivered via a pMDI VHC combination.\n\n               -  Clinically stable asthma.\n\n               -  Cooperative, i.e., subject should be able to follow and understand instructions.\n\n               -  The subject must satisfy the study investigator about his/her fitness to\n                  participate in the study.\n\n        Exclusion Criteria:\n\n          -  Clinically significant respiratory disease in the previous 4 weeks.\n\n          -  Participation in any other clinical trial in the previous 4 weeks.\n\n          -  Lack of cooperation, subject cannot follow and understand instructions."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "8 Years", 
            "minimum_age": "5 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "40 subjects aged 5-8 diagnosed with asthma"
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01714063", 
            "org_study_id": "RDD-2010-001"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pediatric", 
            "asthma", 
            "metered dose inhaler", 
            "valved holding chamber", 
            "pMDI", 
            "VHC"
        ], 
        "lastchanged_date": "April 21, 2014", 
        "location": {
            "contact": {
                "email": "BerlinskiAriel@uams.edu", 
                "last_name": "Ariel Berlinski, MD", 
                "phone": "501-364-1006"
            }, 
            "facility": {
                "address": {
                    "city": "Little Rock", 
                    "country": "United States", 
                    "state": "Arkansas", 
                    "zip": "72202"
                }, 
                "name": "Arkansas Children's Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Drug Delivery Via Pressurized Metered-dose Inhaler and Valved Holding Chamber in Asthmatic Children: Determination of Delivered Dose Following Coordinated and Uncoordinated Use", 
        "other_outcome": {
            "description": "Collect the residual amount of drug (fluticasone) deposited within the OptiChamber Diamond VHC by washing the internal surfaces of the VHC and the pMDI boot", 
            "measure": "Measurement residual amount of drug (fluticasone) deposited within the OptiChamber Diamond VHC", 
            "safety_issue": "No", 
            "time_frame": "Day 1"
        }, 
        "overall_contact": {
            "email": "BerlinskiAriel@uams.edu", 
            "last_name": "Ariel Berlinski, MD", 
            "phone": "501-364-1006"
        }, 
        "overall_official": {
            "affiliation": "University of Arkansas", 
            "last_name": "Ariel Berlinski, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of the present study is to determine ex vivo the amount of fluticasone deposited onto a filter (delivered dose) interposed between the OptiChamber Diamond VHC mouthpiece and the subject's mouth during coordinated and uncoordinated actuation/inhalation maneuver.", 
            "measure": "Delivered dose of fluticasone (on the filter)", 
            "safety_issue": "No", 
            "time_frame": "Day 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01714063"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Correlate inspiratory peak flow and inspiratory tidal volume recorded during the inhalation with amount of drug (fluticasone) deposited on filters attached to the OptiChamber Diamond VHC mouthpiece", 
                "measure": "Inspiratory peak flow", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "Correlate inspiratory peak flow and inspiratory tidal volume recorded during the inhalation with amount of drug (fluticasone) deposited on filters attached to the OptiChamber Diamond VHC mouthpiece", 
                "measure": "Inspiratory tidal volume", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "source": "Philips Respironics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Philips Respironics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2012"
    }
}